Climb Bio, INC DEF 14A proxy statements

Climb Bio, Inc. has issued its 2026 proxy statement detailing director elections, auditor ratification, and proposed amendments to its certificate of incorporation and equity incentive plan.

Climb Bio, Inc. has announced the mutual separation of its Chief Operating Officer and principal financial officer, Brett Kaplan, M.D., effective May 23, 2025, and the immediate appointment of Aoife Brennan as interim principal financial officer.

Climb Bio, Inc. will hold its annual meeting of stockholders virtually on June 4, 2025, to elect two directors and ratify the selection of PricewaterhouseCoopers LLP as its independent auditor.

Climb Bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors and ratify the selection of its independent registered public accounting firm.

Eliem Therapeutics issues a supplement to its definitive proxy statement to address stockholder lawsuits and provide additional information regarding the acquisition of Tenet Medicines, Inc.

Eliem Therapeutics has supplemented its definitive proxy statement regarding the upcoming annual meeting, highlighting the appointment of Aoife Brennan as CEO and Stephen Thomas as a director, contingent on the closing of the Tenet Medicines acquisition.

Eliem Therapeutics plans to acquire Tenet Medicines through a merger, issuing stock and securing a $120 million private placement to advance its immunology and inflammation pipeline.

Eliem Therapeutics is set to acquire Tenet Medicines, enhancing its autoimmune disease pipeline with a concurrent $120 million private placement to advance clinical-stage program TNT119.